Clinical Trial: Fresolimumab In Systemic Sclerosis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL

Brief Summary: The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.